Financial reports
10-Q
2024 Q1
Quarterly report
14 Feb 24
ARS
2023 FY
Annual report to shareholders
8 Feb 24
10-K/A
2023 FY
Annual report (amended)
24 Jan 24
10-K
2023 FY
Annual report
22 Dec 23
10-Q
2023 Q3
Quarterly report
14 Aug 23
10-Q
2023 Q2
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
15 Feb 23
10-Q
2023 Q1
Quarterly report
14 Feb 23
10-K/A
2022 FY
Annual report (amended)
24 Jan 23
10-K
2022 FY
Annual report
29 Dec 22
Current reports
8-K
Unregistered Sales of Equity Securities
15 Apr 24
8-K
Other Events
12 Apr 24
8-K
Other Events
2 Apr 24
8-K
Departure of Directors or Certain Officers
26 Mar 24
8-K
Unregistered Sales of Equity Securities
18 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
7 Mar 24
8-K
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
14 Feb 24
8-K
Entry into a Material Definitive Agreement
24 Jan 24
8-K
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
22 Dec 23
8-K
Departure of Directors or Certain Officers
6 Dec 23
Registration and prospectus
S-3
Shelf registration
26 Apr 24
D
$13.25 mm in equity / options / securities to be acquired, sold $5.00 mm, 1 investor
16 Apr 24
424B5
Prospectus supplement for primary offering
12 Apr 24
424B3
Prospectus supplement
1 Apr 24
D
$159.00 mm in equity / options / securities to be acquired, sold $60.00 mm, 21 investors
29 Mar 24
S-8
Registration of securities for employees
28 Mar 24
S-3
Shelf registration
28 Mar 24
S-3
Shelf registration
25 Mar 24
424B5
Prospectus supplement for primary offering
25 Aug 23
S-3
Shelf registration
14 Aug 23
Proxies
DEF 14A
Definitive proxy
8 Feb 24
PRE 14A
Preliminary proxy
29 Jan 24
DEF 14A
Definitive proxy
15 Feb 23
PRE 14A
Preliminary proxy
27 Jan 23
DEF 14A
Definitive proxy
27 Jan 22
DEF 14A
Definitive proxy
22 Feb 21
PRE 14A
Preliminary proxy
10 Feb 21
DEF 14A
Definitive proxy
18 Aug 20
DEFA14A
Additional proxy soliciting materials
10 Mar 20
DEF 14A
Definitive proxy
14 Feb 20
Other
EFFECT
Notice of effectiveness
8 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
EFFECT
Notice of effectiveness
28 Aug 23
CORRESP
Correspondence with SEC
23 Aug 23
UPLOAD
Letter from SEC
22 Aug 23
EFFECT
Notice of effectiveness
2 Apr 21
CORRESP
Correspondence with SEC
1 Apr 21
UPLOAD
Letter from SEC
31 Mar 21
EFFECT
Notice of effectiveness
20 Apr 20
CORRESP
Correspondence with SEC
16 Apr 20
Ownership
SC 13D/A
Syntone Ventures LLC
17 Apr 24
4
Change in insider ownership
17 Apr 24
SC 13G
GREAT POINT PARTNERS LLC
8 Apr 24
4
Yezan Munther Haddadin
29 Mar 24
SC 13G
Velan Capital Investment Management LP
28 Mar 24
SC 13G
TANG CAPITAL PARTNERS LP
28 Mar 24
4
C RUSSELL TRENARY III
22 Mar 24
4
Jeff Evanson
22 Mar 24
4
LAWRENCE A KENYON
22 Mar 24
SC 13D/A
GMS Ventures & Investments
20 Mar 24